NASDAQ:CBAY - CymaBay Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CymaBay Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.02 +0.06 (+3.06 %) (As of 01/17/2020 04:00 PM ET) Add Compare Today's Range$1.98Now: $2.02▼$2.1850-Day Range$1.62MA: $1.87▼$2.0652-Week Range$1.29Now: $2.02▼$14.00Volume1.87 million shsAverage Volume1.09 million shsMarket Capitalization$138.78 millionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY Previous Symbol CUSIPN/A CIK1042074 Webhttp://www.cymabay.com/ Phone510-293-8800Debt Debt-to-Equity Ratio0.01 Current Ratio13.12 Quick Ratio13.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10 million Price / Sales13.88 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book0.70Profitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-72,550,000.00 Net MarginsN/A Return on Equity-42.36% Return on Assets-39.25%Miscellaneous Employees43 Outstanding Shares68,701,000Market Cap$138.78 million Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive CBAY News and Ratings via Email Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CBAY Rates by TradingView CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions What is CymaBay Therapeutics' stock symbol? CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY." How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics Inc (NASDAQ:CBAY) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.01. View CymaBay Therapeutics' Earnings History. When is CymaBay Therapeutics' next earnings date? CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for CymaBay Therapeutics. What price target have analysts set for CBAY? 13 brokers have issued twelve-month target prices for CymaBay Therapeutics' shares. Their forecasts range from $2.00 to $18.00. On average, they anticipate CymaBay Therapeutics' stock price to reach $6.95 in the next year. This suggests a possible upside of 244.3% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics. What is the consensus analysts' recommendation for CymaBay Therapeutics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CymaBay Therapeutics. What are Wall Street analysts saying about CymaBay Therapeutics stock? Here are some recent quotes from research analysts about CymaBay Therapeutics stock: 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (1/7/2020) 2. HC Wainwright analysts commented, "916-3963, Rating POS Risk-adj value Full value Shares outstanding 68,696 S/O as of April 30, 2019. Current share price $6.05 Discount rate 20.0% Seladelpar (PBC) – U.S." (6/12/2019) 3. Cantor Fitzgerald analysts commented, ". Reiterate our Overweight rating; increasing 12-mo. PT to $20. CymaBay is a liver disease company with lead asset, seladelpar, in Ph3 for primary biliary cholangitis (PBC). Our checks suggest seladelpar’s strong profile in PBC has the potential to grow the market significantly from where it is today. We think the opportunity in PBC alone (~$350M in 2026 unadjusted sales vs. cap of $500M) should justify upside. We see further potential for seladelpar with a 2Q19 Ph2b NASH proof of concept readout, which could be a much larger opportunity (~ $4B+) for Seladelpar if successful. In our 75-page slide deck, we took a close look at PPAR-delta biology & role in NASH. Our Take: PPAR-delta has the potential to be a major target in the NASH space." (2/1/2019) Has CymaBay Therapeutics been receiving favorable news coverage? Headlines about CBAY stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CymaBay Therapeutics earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for CymaBay Therapeutics. Are investors shorting CymaBay Therapeutics? CymaBay Therapeutics saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 7,160,000 shares, an increase of 5.3% from the November 28th total of 6,800,000 shares. Based on an average trading volume of 2,070,000 shares, the short-interest ratio is currently 3.5 days. Currently, 11.7% of the company's shares are short sold. View CymaBay Therapeutics' Current Options Chain. Who are some of CymaBay Therapeutics' key competitors? Some companies that are related to CymaBay Therapeutics include MacroGenics (MGNX), Clovis Oncology (CLVS), Viking Therapeutics (VKTX), Magenta Therapeutics (MGTA), BioDelivery Sciences International (BDSI), Neoleukin Therapeutics (NLTX), OrganiGram (OGI), Molecular Templates (MTEM), Dynavax Technologies (DVAX), Organogenesis (ORGO), Arcus Biosciences (RCUS), DURECT (DRRX), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX) and Mirum Pharmaceuticals (MIRM). What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Energy Transfer LP Unit (ET), Viking Therapeutics (VKTX), Alibaba Group (BABA), Abeona Therapeutics (ABEO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Progenics Pharmaceuticals (PGNX) and Synergy Pharmaceuticals (SGYP). Who are CymaBay Therapeutics' key executives? CymaBay Therapeutics' management team includes the folowing people: Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)Mr. Daniel Menold, VP of Fin. (Age 49)Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)Dr. Pol F. Boudes, Chief Medical Officer (Age 62) Who are CymaBay Therapeutics' major shareholders? CymaBay Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Diversified Trust Co (0.03%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Daniel Menold, Kurt Von Emster and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics. Which institutional investors are buying CymaBay Therapeutics stock? CBAY stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View Insider Buying and Selling for CymaBay Therapeutics. How do I buy shares of CymaBay Therapeutics? Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is CymaBay Therapeutics' stock price today? One share of CBAY stock can currently be purchased for approximately $2.02. How big of a company is CymaBay Therapeutics? CymaBay Therapeutics has a market capitalization of $138.78 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-72,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.View Additional Information About CymaBay Therapeutics. What is CymaBay Therapeutics' official website? The official website for CymaBay Therapeutics is http://www.cymabay.com/. How can I contact CymaBay Therapeutics? CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected] MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 401 (Vote Outperform)Underperform Votes: 281 (Vote Underperform)Total Votes: 682MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2020 by MarketBeat.com StaffFeatured Article: Why Invest in Dividend Achievers?
